Toward the therapeutic editing of mutated RNA sequences. Computer simulations explain mutation-induced effects on the DNA editing by adenine base editors. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. This paper reports the development of the first ABEs and the most widely used variant, ABE7.10, capable of installing A
#Base one technologies archive#
ClinVar: public archive of interpretations of clinically relevant variants. This paper is the initial report of DdCBE, the first base editor developed for mitochondrial base editing. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Engineering and optimising deaminase fusions for genome editing.
DNA mismatch repair in eukaryotes and bacteria.
Mismatched repair: variations on a theme. Crystal structure of Cas9 in complex with guide RNA and target DNA. This paper reports the development of the first DNA base editors, BE1, BE2 and BE3, capable of installing C Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. TALENs: a widely applicable technology for targeted genome editing. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR–Cas9. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. RNA-targeting CRISPR–Cas systems and their applications. Advances in genome editing through control of DNA repair pathways. Nuclear domain ‘knock-in’ screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR–Cas9 using asymmetric donor DNA. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR–Cas9 RNP and AAV6 donor-mediated homologous recombination. RNA-guided human genome engineering via Cas9. Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. This landmark paper reports the mechanistic elucidation of SpCas9 for programmable double-stranded DNA break introduction, demonstrating its potential for subsequent use as a genome editing agent. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. CRISPR-based technologies for the manipulation of eukaryotic genomes. Efficient and allele-specific genome editing of disease loci in human iPSCs. Genomic characterization of metastatic breast cancers. A general framework for estimating the relative pathogenicity of human genetic variants. Non-coding genetic variants in human disease. Single nucleotide variations: biological impact and theoretical interpretation. A global reference for human genetic variation. New insights into the pathogenicity of non-synonymous variants through multi-level analysis.
0 kommentar(er)
